{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:31:02Z","timestamp":1762867862851,"version":"build-2065373602"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-025-11160-4","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:17:53Z","timestamp":1762867073000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["METTL3 drives malignant progression in TP53-mutant prostate cancer"],"prefix":"10.1007","volume":"53","author":[{"given":"Yong","family":"Pu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaowei","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"11160_CR1","doi-asserted-by":"publisher","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. https:\/\/doi.org\/10.3322\/caac.21834","DOI":"10.3322\/caac.21834"},{"key":"11160_CR2","doi-asserted-by":"crossref","unstructured":"James ND, Tannock I, N\u2019Dow J, Feng F, Gillessen S, Ali SA, Trujillo B, Al-Lazikani B, Attard G, Bray F et al (2024) The lancet commission on prostate cancer: planning for the surge in cases. Lancet","DOI":"10.1016\/S0140-6736(24)00651-2"},{"issue":"10","key":"11160_CR3","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/S1470-2045(09)70229-3","volume":"10","author":"Y Chen","year":"2009","unstructured":"Chen Y, Clegg NJ, Scher HI (2009) Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol 10(10):981\u2013991","journal-title":"Lancet Oncol"},{"issue":"1","key":"11160_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","volume":"18","author":"BS Taylor","year":"2010","unstructured":"Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18(1):11\u201322","journal-title":"Cancer Cell"},{"issue":"6","key":"11160_CR5","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","volume":"170","author":"ER Kastenhuber","year":"2017","unstructured":"Kastenhuber ER, Lowe SW (2017) Putting p53 in context. Cell 170(6):1062\u20131078","journal-title":"Cell"},{"issue":"3","key":"11160_CR6","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41568-023-00658-3","volume":"24","author":"S Peuget","year":"2024","unstructured":"Peuget S, Zhou X, Selivanova G (2024) Translating p53-based therapies for cancer into the clinic. Nat Rev Cancer 24(3):192\u2013215","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"11160_CR7","first-page":"378","volume":"16","author":"J Wan","year":"2018","unstructured":"Wan J, Zhang J, Zhang J (2018) Expression of p53 and its mechanism in prostate cancer. Oncol Lett 16(1):378\u2013382","journal-title":"Oncol Lett"},{"issue":"23","key":"11160_CR8","doi-asserted-by":"publisher","first-page":"11428","DOI":"10.1073\/pnas.1902651116","volume":"116","author":"W Abida","year":"2019","unstructured":"Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, Cieslik M, Benelli M, Robinson D, Van Allen EM et al (2019) Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci U S A 116(23):11428\u201311436","journal-title":"Proc Natl Acad Sci U S A"},{"key":"11160_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.04.009","author":"Y Liu","year":"2024","unstructured":"Liu Y, Su Z, Tavana O, Gu W (2024) Understanding the complexity of p53 in a new era of tumor suppression. Cancer Cell. https:\/\/doi.org\/10.1016\/j.ccell.2024.04.009","journal-title":"Cancer Cell"},{"key":"11160_CR10","doi-asserted-by":"crossref","unstructured":"Beier AK, Ebersbach C, Siciliano T, Scholze J, Hofmann J, H\u00f6nscheid P, Baretton GB, Woods K, Guezguez B, Dubrovska A et al (2024) Targeting the glutamine metabolism to suppress cell proliferation in mesenchymal docetaxel-resistant prostate cancer. Oncogene","DOI":"10.1038\/s41388-024-03059-4"},{"issue":"1","key":"11160_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01042-7","volume":"7","author":"Y He","year":"2022","unstructured":"He Y, Xu W, Xiao YT, Huang H, Gu D, Ren S (2022) Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. Signal Transduct Target Ther 7(1):198","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"11160_CR12","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.ccr.2014.01.021","volume":"25","author":"PA Muller","year":"2014","unstructured":"Muller PA, Vousden KH (2014) Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell 25(3):304\u2013317","journal-title":"Cancer Cell"},{"issue":"8","key":"11160_CR13","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41571-023-00774-x","volume":"20","author":"X Deng","year":"2023","unstructured":"Deng X, Qing Y, Horne D, Huang H, Chen J (2023) The roles and implications of RNA m(6)A modification in cancer. Nat Rev Clin Oncol 20(8):507\u2013526","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"11160_CR14","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020105977","volume":"40","author":"PC He","year":"2021","unstructured":"He PC, He C (2021) M(6) a RNA methylation: from mechanisms to therapeutic potential. EMBO J 40(3):e105977","journal-title":"EMBO J"},{"issue":"7683","key":"11160_CR15","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/nature24678","volume":"552","author":"I Barbieri","year":"2017","unstructured":"Barbieri I, Tzelepis K, Pandolfini L, Shi J, Mill\u00e1n-Zambrano G, Robson SC, Aspris D, Migliori V, Bannister AJ, Han N et al (2017) Promoter-bound METTL3 maintains myeloid leukaemia by m(6)a-dependent translation control. Nature 552(7683):126\u2013131","journal-title":"Nature"},{"issue":"9","key":"11160_CR16","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1016\/j.molcel.2022.02.033","volume":"82","author":"J Xiong","year":"2022","unstructured":"Xiong J, He J, Zhu J, Pan J, Liao W, Ye H, Wang H, Song Y, Du Y, Cui B et al (2022) Lactylation-driven METTL3-mediated RNA m(6)A modification promotes immunosuppression of tumor-infiltrating myeloid cells. Mol Cell 82(9):1660\u20131677e1610","journal-title":"Mol Cell"},{"issue":"7860","key":"11160_CR17","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41586-021-03536-w","volume":"593","author":"E Yankova","year":"2021","unstructured":"Yankova E, Blackaby W, Albertella M, Rak J, De Braekeleer E, Tsagkogeorga G, Pilka ES, Aspris D, Leggate D, Hendrick AG et al (2021) Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature 593(7860):597\u2013601","journal-title":"Nature"},{"issue":"1","key":"11160_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16306-5","volume":"11","author":"Z Li","year":"2020","unstructured":"Li Z, Peng Y, Li J, Chen Z, Chen F, Tu J, Lin S, Wang H (2020) N(6)-methyladenosine regulates glycolysis of cancer cells through PDK4. Nat Commun 11(1):2578","journal-title":"Nat Commun"},{"issue":"1","key":"11160_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25803-0","volume":"12","author":"H Song","year":"2021","unstructured":"Song H, Song J, Cheng M, Zheng M, Wang T, Tian S, Flavell RA, Zhu S, Li HB, Ding C et al (2021) METTL3-mediated m(6)a rna methylation promotes the anti-tumour immunity of natural killer cells. Nat Commun 12(1):5522","journal-title":"Nat Commun"},{"issue":"4","key":"11160_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05773-5","volume":"14","author":"Y Li","year":"2023","unstructured":"Li Y, Zhu S, Chen Y, Ma Q, Kan D, Yu W, Zhang B, Chen X, Wei W, Shao Y et al (2023) Post-transcriptional modification of m(6)A methylase METTL3 regulates ERK-induced androgen-deprived treatment resistance prostate cancer. Cell Death Dis 14(4):289","journal-title":"Cell Death Dis"},{"key":"11160_CR21","doi-asserted-by":"publisher","first-page":"9143","DOI":"10.2147\/OTT.S226796","volume":"12","author":"J Cai","year":"2019","unstructured":"Cai J, Yang F, Zhan H, Situ J, Li W, Mao Y, Luo Y (2019) RNA m(6)a methyltransferase METTL3 promotes the growth of prostate cancer by regulating Hedgehog pathway. Onco Targets Ther 12:9143\u20139152","journal-title":"Onco Targets Ther"},{"issue":"3","key":"11160_CR22","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ccell.2020.02.004","volume":"37","author":"H Huang","year":"2020","unstructured":"Huang H, Weng H, Chen J (2020) M(6)A modification in coding and non-coding rnas: roles and therapeutic implications in cancer. Cancer Cell 37(3):270\u2013288","journal-title":"Cancer Cell"},{"issue":"6","key":"11160_CR23","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s41594-021-00606-5","volume":"28","author":"J Li","year":"2021","unstructured":"Li J, Gregory RI (2021) Mining for METTL3 inhibitors to suppress cancer. Nat Struct Mol Biol 28(6):460\u2013462","journal-title":"Nat Struct Mol Biol"},{"issue":"19","key":"11160_CR24","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1002\/cmdc.202100291","volume":"16","author":"EV Moroz-Omori","year":"2021","unstructured":"Moroz-Omori EV, Huang D, Kumar Bedi R, Cheriyamkunnel SJ, Bochenkova E, Dolbois A, Rzeczkowski MD, Li Y, Wiedmer L, Caflisch A (2021) Mettl3 inhibitors for epitranscriptomic modulation of cellular processes. ChemMedChem 16(19):3035\u20133043","journal-title":"ChemMedChem"},{"issue":"4","key":"11160_CR25","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/pros.24290","volume":"82","author":"K Sienkiewicz","year":"2022","unstructured":"Sienkiewicz K, Yang C, Paschal BM, Ratan A (2022) Genomic analyses of the metastasis-derived prostate cancer cell lines LNCaP, VCaP, and PC3-AR. Prostate 82(4):442\u2013451","journal-title":"Prostate"},{"issue":"1","key":"11160_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01705-z","volume":"8","author":"ME Bahar","year":"2023","unstructured":"Bahar ME, Kim HJ, Kim DR (2023) Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies. Signal Transduct Target Ther 8(1):455","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"11160_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3000872","volume":"18","author":"Y Lv","year":"2020","unstructured":"Lv Y, Wang X, Li X, Xu G, Bai Y, Wu J, Piao Y, Shi Y, Xiang R, Wang L (2020) Nucleotide de novo synthesis increases breast cancer stemness and metastasis via cGMP-PKG-MAPK signaling pathway. PLoS Biol 18(11):e3000872","journal-title":"PLoS Biol"},{"issue":"7793","key":"11160_CR28","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41586-020-1969-6","volume":"578","author":"Pan-cancer analysis of whole genomes","year":"2020","unstructured":"Pan-cancer analysis of whole genomes (2020) Nature 578(7793):82\u201393","journal-title":"Nature"},{"issue":"4","key":"11160_CR29","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.ccell.2021.01.003","volume":"39","author":"M Ghosh","year":"2021","unstructured":"Ghosh M, Saha S, Bettke J, Nagar R, Parrales A, Iwakuma T, van der Velden AWM, Martinez LA (2021) Mutant p53 suppresses innate immune signaling to promote tumorigenesis. Cancer Cell 39(4):494\u2013508e495","journal-title":"Cancer Cell"},{"issue":"7568","key":"11160_CR30","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/nature15251","volume":"525","author":"J Zhu","year":"2015","unstructured":"Zhu J, Sammons MA, Donahue G, Dou Z, Vedadi M, Getlik M, Barsyte-Lovejoy D, Al-awar R, Katona BW, Shilatifard A et al (2015) Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth. Nature 525(7568):206\u2013211","journal-title":"Nature"},{"issue":"7","key":"11160_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112704","volume":"42","author":"T Wei","year":"2023","unstructured":"Wei T, Li J, Zhang J, Zhang Q, Liu X, Chen Q, Wen L, Ma K, Chen W, Zhao J et al (2023) Loss of Mettl3 enhances liver tumorigenesis by inducing hepatocyte dedifferentiation and hyperproliferation. Cell Rep 42(7):112704","journal-title":"Cell Rep"},{"issue":"6","key":"11160_CR32","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.cmet.2021.03.024","volume":"33","author":"H Ramalingam","year":"2021","unstructured":"Ramalingam H, Kashyap S, Cobo-Stark P, Flaten A, Chang CM, Hajarnis S, Hein KZ, Lika J, Warner GM, Espindola-Netto JM et al (2021) A methionine-Mettl3-N(6)-methyladenosine axis promotes polycystic kidney disease. Cell Metab 33(6):1234\u20131247e1237","journal-title":"Cell Metab"},{"issue":"3","key":"11160_CR33","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.molcel.2020.06.017","volume":"79","author":"C Zhang","year":"2020","unstructured":"Zhang C, Chen L, Peng D, Jiang A, He Y, Zeng Y, Xie C, Zhou H, Luo X, Liu H et al (2020) METTL3 and N6-Methyladenosine promote homologous Recombination-Mediated repair of DSBs by modulating DNA-RNA hybrid accumulation. Mol Cell 79(3):425\u2013442e427","journal-title":"Mol Cell"},{"issue":"10","key":"11160_CR34","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1158\/2159-8290.CD-23-0007","volume":"13","author":"AA Guirguis","year":"2023","unstructured":"Guirguis AA, Ofir-Rosenfeld Y, Knezevic K, Blackaby W, Hardick D, Chan YC, Motazedian A, Gillespie A, Vassiliadis D, Lam EYN et al (2023) Inhibition of METTL3 results in a cell-intrinsic interferon response that enhances antitumor immunity. Cancer Discov 13(10):2228\u20132247","journal-title":"Cancer Discov"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-11160-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-11160-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-11160-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:18:01Z","timestamp":1762867081000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-11160-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11160"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-11160-4","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"assertion":[{"value":"29 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"66"}}